Answer
Lebrikizumab (Ebglyss) is indicated for moderate-to-severe atopic dermatitis in adults and adolescents aged 12 years and older weighing at least 40 kg who are candidates for systemic therapy.
Sources for this answer
- Ebglyss 250 mg solution for injection in pre-filled syringeAlmirall Limited · emc · SmPC §4.1 Therapeutic Indications · Version 5Document updated
Sources checked